Oscar Health, Inc.
NYSE:OSCRMedical - Healthcare Plans
+$0.05 today
- Market cap
- $7.15B
- Beta
- 2.39
- P/E (TTM)
- -214.2
- EPS (TTM)
- -$0.13
Volume 7.38M
Average 7.51M
OSCR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Oscar Health, Inc.NYSE: OSCR
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $6.03M fell 13.5% year over year, behind the -7.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 14.1% from the prior quarter. Over 3 fiscal years it compounded at +23.6% a year.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of -7.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 28.89M USD
- Year-over-year change
- -10.1%
- 4-year CAGR
- +18.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.89M | -10.1% |
| FY2024 | 2024-12-31 | 32.15M | +4.7% |
| FY2023 | 2023-12-31 | 30.69M | +100.8% |
| FY2022 | 2022-12-31 | 15.28M | +4.6% |
| FY2021 | 2021-12-31 | 14.61M | — |
Depreciation & Amortization vs competitors
How OSCR compares with its peers on the latest reported figures
- OSCR's LTM Jun 2026 depreciation & amortization of $28.24M is the 7th largest of the 8 companies compared; the peer median is $1.25B.
- Its year-over-year change of -7.2% is the 7th highest of 8, against a peer median of -0.8%.
- Depreciation & amortization amounts to 0.2% of revenue for OSCR, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Sep 2026 | $1.49B | -3.2% | -2.6% | 0.7% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $161M | -19.1% | +3.5% | 0.4% | |
| LTM Mar 2026 | $30.72M | +7.2% | +21.8% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| LTM Jun 2026 | $1.91M | +23.5% | +12.4% | 0.1% | |
| Peer median (excluding OSCR) | $1.25B | -0.8% | +2.9% | 0.7% | |
Competitors are the stored peer set for OSCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (571.43M) | (609.55M) | (270.59M) | 26.12M | (442.9M) |
| Depreciation & Amortization | 14.61M | 15.28M | 30.69M | 32.15M | 28.89M |
| Deferred Income Tax | (101K) | (165K) | 58K | (2.34M) | 2.45M |
| Stock-Based Compensation | 86.3M | 112.33M | 159.68M | 109.82M | 87.65M |
| Change in Working Capital | 247.7M | 855M | (192.09M) | 838.86M | 1.46B |
| Accounts Receivables | 80.45M | (551.15M) | 636.23M | (177.52M) | 98.57M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (39.46M) | 280.23M | (395.81M) | 133.09M | 167.72M |
| Other Working Capital | 206.71M | 1.13B | (432.51M) | 883.29M | 1.19B |
| Other Non-Cash Items | 41.19M | 7.46M | 86K | (26.42M) | (40.24M) |
| Operating Cash Flow | (181.75M) | 380.35M | (272.16M) | 978.19M | 1.09B |
| Capital Expenditures | (25.89M) | (29.01M) | (25.58M) | (27.9M) | (36.37M) |
| Acquisitions (Net) | 7.23M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.81B) | (1.19B) | (836.98M) | (2.13B) | (1.01B) |
| Sales of Investments | 1.05B | 994.08M | 1.44B | 770.04M | 804.96M |
| Other Investing Activities | (555K) | 1.12M | (2.28M) | 3.93M | 4.28M |
| Investing Cash Flow | (774.52M) | (226.52M) | 577.19M | (1.39B) | (241.06M) |
| Debt Repayment | (153.17M) | 305M | 0 | 0 | 348.21M |
| Common Stock Issued | 1.35B | 1.3M | 3.96M | 68.39M | 55.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.56M | (5.19M) | 2.49M | 0 | (4.04M) |
| Financing Cash Flow | 1.24B | 301.11M | 6.45M | 68.39M | 399.21M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 282.45M | 454.94M | 311.47M | (340.85M) | 1.25B |
| Free Cash Flow | (207.63M) | 351.34M | (297.74M) | 950.3M | 1.06B |
Oscar Health, Inc.
NYSE:OSCR
Intrinsic Alpha fair value
Locked
Current Price
$27.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.